Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSQ3AZ)

• Drug Name: JNJ-26483327 Drug Info
• Synonyms: MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 11952856
  TTD Drug ID: DMSQ3AZ

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor receptor 3 (FLT-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[4]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[5]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[7]
PI-88	DMGZPX6	Hepatocellular carcinoma	2C12.02	Phase 3	[8]
Taberminogene vadenovec	DMW5PHL	Vascular restinosis	BE2Z	Phase 3	[9]
ABT-869	DMREDYP	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[11]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]
VATALANIB	DMY0UEQ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]

Drug(s) Targeting LCK tyrosine protein kinase (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[14]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[15]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[16]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[16]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[17]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[16]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[18]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[19]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[16]

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[20]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[21]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[22]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[23]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[24]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[25]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[26]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[27]
Pertuzumab	DMHJV0X	Adrenal gland neoplasm		Approved	[28]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[29]

Drug(s) Targeting Fyn tyrosine protein kinase (FYN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[14]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[30]
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[31]
CEP-5104	DMV43GY	Discovery agent	N.A.	Investigative	[32]
CEP-6331	DMNXBTD	Discovery agent	N.A.	Investigative	[32]
JNJ-10198409	DM9GDP5	Discovery agent	N.A.	Investigative	[33]
1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane	DMD7WNV	Discovery agent	N.A.	Investigative	[34]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[35]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[20]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[36]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[37]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[14]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[38]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[22]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[39]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[38]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[23]

Drug(s) Targeting Tyrosine-protein kinase Lyn (JTK8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bafetinib	DM7586F	Bone disease	FC0Z	Phase 2	[40]
Alkynyl-substituted pyrimidinyl-pyrrole derivative 1	DMK7DJ2	N. A.	N. A.	Patented	[41]
NG-25	DMC48D9	Discovery agent	N.A.	Investigative	[42]
PMID17600705C23	DMJFOGW	Discovery agent	N.A.	Investigative	[43]

Drug(s) Targeting Yes tyrosine kinase (YES)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TG-100435	DMIR3X2	Discovery agent	N.A.	Investigative	[44]

Drug(s) Targeting Erbb4 tyrosine kinase receptor (Erbb-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[21]
RG7388	DMF5GZI	Acute myeloid leukaemia	2A60	Phase 3	[45]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[14]
JI-101	DMM02VJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[46]
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[47]
HDS-029	DMLRUVA	Discovery agent	N.A.	Investigative	[48]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[2]
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Inhibitor	[2]
Erbb4 tyrosine kinase receptor (Erbb-4)	TT0JESD	ERBB4_HUMAN	Inhibitor	[2]
Fyn tyrosine protein kinase (FYN)	TT2B9KF	FYN_HUMAN	Inhibitor	[3]
LCK tyrosine protein kinase (LCK)	TT860QF	LCK_HUMAN	Inhibitor	[2]
Tyrosine-protein kinase Lyn (JTK8)	TT1RWNJ	LYN_HUMAN	Inhibitor	[2]
Vascular endothelial growth factor receptor 3 (FLT-4)	TTDCBX5	VGFR3_HUMAN	Inhibitor	[2]
Yes tyrosine kinase (YES)	TT0SQ8J	YES_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT00676299) A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.. U.S. National Institutes of Health.
• [2] National Cancer Institute Drug Dictionary (drug id 596693).
• [3] National Cancer Institute Drug Dictionary (drug id 596693).
• [4] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [6] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [7] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [8] Company report (Medigen)
• [9] Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
• [10] Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814).
• [12] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [13] Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
• [14] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [15] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [16] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [17] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [18] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [19] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [20] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [22] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [23] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [24] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [25] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [26] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [27] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [28] Clinical pipeline report, company report or official report of Roche (2009).
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [30] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [31] Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
• [32] Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
• [33] (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
• [34] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [35] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [36] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [37] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [38] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [39] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [40] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [41] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
• [42] Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
• [43] N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
• [44] Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
• [45] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1799).
• [46] A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.Invest New Drugs.2015 Dec;33(6):1217-24.
• [47] Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
• [48] Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.